Beta-blockers in Heart Failure: Where Do We Stand Today?
Beta-blockers, which hitherto have been considered contraindicated for treatment of congestive heart failure, have recently been accepted for symptomatic treatment. The rationale for beta-blockers has become evident thanks to the concept of neuroendocrine activation in congestive heart failure and progress in molecular biology. There are strong data indicating that beta-blockers improve myocardial metabolism and efficacy, exert antioxidant effect, and reduce apoptosis. These results could explain the improved systolic and diastolic function, well-being, and slowing-down of disease progression. Placebo-controlled trials have shown to reduce morbidity, prevent heart transplantation, and recently also to cause overall reduction in mortality. It is now time to include betablockers in our standard armamentarium for heart failure treatment.
Key wordsBeta-blockers Heart failure
Unable to display preview. Download preview PDF.
- 3.Lechat P, Escolano S, Golmard JL, Lardoux H, Witchitz S. Henneman JA, Maisch B, Hetzel M, Jaillon P, Boissel JP, Mallet A (1997) Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study ( CIBIS ). Circulation 96: 2197–2105PubMedGoogle Scholar
- 7.Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB (1989) Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483–490PubMedCrossRefGoogle Scholar
- 9.Waagstein F, Wahlquist I, Andersson B, Böhm M. Darius M, Delius R, Dietz R, Goss F, Sigmund M, Stroemblad SO, Trenkwalder P (1998) For the metoprolol in mild to moderate heart failure study group. Metoprolol prevents left ventricular dilatation and increases exercise ejection fraction to the same extent in idiopathic dilated and ischemic cardiomyopathy. Eur Heart J 19 (suppl): 307Google Scholar
- 11.Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss F, Hjalmarson A (1993) For the Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441–1446PubMedCrossRefGoogle Scholar
- 14.Wiklund I, Waagstein F, Swedberg K, Hjalmarson A (1996) Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardivasc Drugs Ther 10: 361–368Google Scholar
- 19.Andersson B, Lomsky M, Waagstein F (1993) The link between acute hemodynamic adrenergic beta-blockade and long-term effects in patients with heart failure: a study of diastolic function, heart rate and myocardial metabolism following intravenous metoprolol. Eur Heart J 14: 1375–1385PubMedCrossRefGoogle Scholar
- 21.The Cardiac Insufficiency Bisoprolol Study (CIBIS) CIBIS Investigators and Committees (1994) Randomized trial of beta-blockade in heart failure. Circulation 90: 1765–1773Google Scholar
- 24.Herlitz J, Waagstein F, Lindquist J, Swedberg K, Hjalmarson A (1977) Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Goteborg Metoprolol Trial). Am J Cardiol 80 (9B): 40J - 44JCrossRefGoogle Scholar
- 28.Sabbah HN, Sharov VG, Goussev A, Shimoyama H, Goildstein S (1998) Long-term beta-blockade with metoprolol attenautes cardiocyte apoptosis in dogs with moderate heart failure. Eur Heart J 19 (suppl): 353Google Scholar
- 29.Fesmire SI, Eichhorn EJ, Kennedy HL, Marcoux LG, Lyyski DS, Sprague MK (1998) Improvement in QT-dispersion with selective vs. non-selective beta-blockade in patients with dilated cardiomyopathy. Eur Heart J 19 (suppl): 307Google Scholar
- 30.Andersson B, Caidahl K, diLenarda A, Warren SE, Goss F, Waldenstrom A, Persson S, Wallentin I, Hjalmarson A, Waagstein F (1996) Changes in early and late diastolic filling patterns induced by long-term adrenergic blockade in patients with idiopathic dilated cardiomyopathy. Circulation 94: 673–682PubMedGoogle Scholar
- 31.Jahns R, Jensen M, Jahns V, Lohse MJ, Inselman G (1998) A new role for cardioselective beta-receptor antagonists: blocking the effects of sensitizing autoantibodies in dilated cardiomyopathy that are associated with impaired left ventriuclar function. Eur Heart J 19 (suppl): 462Google Scholar